drugset / Trial / NCT00157872

A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)

NCT00157872

Phase 4 Completed 150 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.

Timeline

Start
2004-01-07
Primary completion
2004-07-05
Completion
2004-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 500 mg
Subject rofecoxib Small molecule 25 mg

Indications